Cerulean Pharma Inc. CEO to Present at BioPharm AmericaTM 2010

Oliver Fetzer to Showcase Strong Company Progress at Partnering Conference and Investors Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in nanopharmaceuticals, today announced that the Company’s chief executive, Oliver Fetzer, Ph.D., will present at the BioPharm America^TM conference being held in Boston, Massasachusetts, from September 15-17, 2010. The premier pharmaceutical partnership conference has joined forces with MassBio Investors Forum to bring together pharmaceutical industry executives and life science investors for one of the largest and most productive partnering events. Dr. Fetzer will brief attendees on Cerulean’s key accomplishments and positive momentum.

“Cerulean is leading the industry with CRLX101’s progression as a first-in-class nanopharmaceutical into Phase 2a development, which speaks to the strength of our platform”

A key accomplishment that Dr. Fetzer will highlight is the Company’s initiation of a multi-site Phase 2a clinical study of its first-in-class nanopharmaceutical, CRLX101, in advanced cancer patients. Findings from Cerulean’s Phase 1 study with CRLX101 demonstrated clinical activity in several patients and a favorable safety profile. These data were presented at the recent 2010 American Chemical Society National Meeting & Exposition held last month in Boston, Massachusetts.

Dr. Fetzer will also describe the advancement of the Company’s lead pre-clinical candidate, CRLX288, a novel docetaxel nanopharmaceutical. Docetaxel is one of the most widely prescribed oncology drugs and is efficacious in many solid tumors. CRLX288 has been designed to further enhance the efficacy of docetaxel by maximizing drug exposure in cancer cells while at the same time minimizing bone marrow toxicity, neurotoxicity, and drug resistance, which are some of docetaxel’s clinical limitations.

“Cerulean is leading the industry with CRLX101’s progression as a first-in-class nanopharmaceutical into Phase 2a development, which speaks to the strength of our platform,” said Dr. Fetzer. “Last month we presented data showing that our nanoparticles are stable in the bloodstream, preferentially accumulate in target disease tissues, penetrate deeply in tumors, and are taken up by cancer cells. Cerulean’s nanopharmaceutical platform is unique in realizing these biological benefits, making it of keen interest to pharmaceutical companies and investors in cancer drug development, as well as in other therapeutic areas such as inflammation. We are excited about the progress Cerulean has made validating the nanopharmaceutical platform pre-clinically and increasingly in the clinic.”

Dr. Fetzer will present at 9:00 a.m. on Friday, September 17, in the Clarendon Room in Marriott Boston Copley, Boston, Massachusetts.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.